Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ: EXAS )

49.31 -1.28 (-2.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Forecasting The Future: 19 Analyst Projections For Exact Sciences
Via Benzinga
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone
The company is working to expand the uses and reimbursement for its blood-based tests for cancer. 
Via Investor's Business Daily
Exact Sciences Stock Drops 12% Over Four Days. 'What Is Going On?'
The company is facing numerous headline risks. But not all of them are legitimate, says one analyst. 
Via Investor's Business Daily
2 Healthcare Stocks to Buy Hand Over Fist in January
Via The Motley Fool
Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market
Exact Sciences' 2024 sales grew 10% to $2.76 billion, exceeding estimates. New cancer tests, including Cologuard Plus, are set for 2025 launch. 
Via Benzinga
(EXAS) - Analyzing Exact Sciences's Short Interest
Via Benzinga
What 19 Analyst Ratings Have To Say About Exact Sciences
Via Benzinga
Will EXACT SCIENCES CORP breakout?
With a solid technical rating of 8 out of 10, EXACT SCIENCES CORP (NASDAQ:EXAS) is showing strong indications of a possible breakout. 
Via Chartmill
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP. 
Via Benzinga
Why Is Exact Sciences Stock Trading Higher On Monday?
Centers for Medicare & Medicaid Services finalizes 2025 pricing for Exact Sciences' Cologuard Plus, raising Medicare reimbursement by 16% and boosting growth projections for next year. 
Via Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks
U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.'s largest trading partners - Canada and Mexico - with... 
Via Benzinga
Topics Government
Exposures Political
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
(EXAS) - Analyzing Exact Sciences's Short Interest
Via Benzinga
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?
The company reported lighter-than-expected third-quarter sales due to issues with physician order rates. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment hurdles, growth plans set for 2025. 
Via Benzinga
Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Analyst Ratings For Exact Sciences
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Exact Sciences
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript
EXAS earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates
Exact Sciences shares are dropping after the company reported its third-quarter results after Tuesday's closing bell. Here's a look at the details. 
Via Benzinga
Can This Beaten-Down Cathie Wood Stock Bounce Back?
An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback. 
Via The Motley Fool
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average risk for colorectal cancer. The test outperformed fecal immunochemical tests in... 
Via Benzinga
Exposures Product Safety
Exact Sciences Stock Rises After FDA Signs Off On New Cologuard
The company is soon to launch its next-generation colon cancer screening tool. 
Via Investor's Business Daily
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.